September 10, 2020 Impact: Moderate Gemini Therapeutics enrolls first patients for its phase 2a ReGAtta study to evaluate the safety and efficacy of GEM-103 for the treatment of patients with GA secondary to dry AMD. The study will recruit…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-09-16 13:07:192020-09-16 13:07:19Gemini Therapeutics Enrolls First Patient for its Phase 2a Study of GEM-103 in GA
September 1, 2020 Impact: Moderate Gilead has reached an exclusive licensing agreement for Jounce Therapeutic’s JTX-1811. JTX-1811 is a monoclonal antibody (mAb) that targets CCR8 to deplete immunosuppressive tumor-infiltrating T regulatory…
August 25, 2020 Impact: Moderate
Highlights
Immunovant reported topline results for its Phase 2a ASCEND-MG trial of IMVT-1401, an SC anti-FcRN, in MG: Three arms were included (6 weeks treatment period with weekly dosing): 340 mg…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-09-01 20:19:352020-09-01 20:19:35Immunovant Announces Positive Topline Results from its Phase 2a ASCEND-MG Trial of IMVT-1401 in MG
August 20, 2020 Impact: Moderate Gilead and Tango will expand a 2018 agreement into a multi-year discovery, development, and commercialization collaboration of novel immune evasion therapies in oncology.
The deal structure includes: …
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-08-26 13:07:262020-08-26 13:07:26Gilead Builds on Oncology Portfolio with Expansion of Tango Therapeutics Partnership
August 6, 2020 Impact: High Biogen and Denali Therapeutics announced an agreement to co-develop and co-commercialize Denali's small molecule LRRK2 franchise for PD. Biogen receives the rights to opt into two programs, and rights of first…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-08-12 14:02:542020-08-12 14:02:54Denali to Collaborate with Biogen on LRRK2 Program: Advances DNL151 into Late-Stage Studies
July 22, 2020 Impact: High GENFIT has officially terminated its pivotal RESOLVE-IT trial of elafibranor for the treatment of NASH with fibrosis after it failed an interim analysis back in May.
The trial did not meet the predefined…